Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TJ271 + pembrolizumab
- Development stage
- Phase 1
- Lead developer
- I-MAB
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TJ271 + pembrolizumab is a combination therapy under investigation for the treatment of advanced solid tumors. Pembrolizumab is a humanized monoclonal antibody that targets programmed cell death protein 1 (PD-1), blocking its interaction with PD-L1 and PD-L2 to enhance anti-tumor immune responses. It is approved for multiple cancers and marketed as Keytruda. TJ271 is an investigational agent being evaluated in combination with pembrolizumab in phase II clinical trials in China for advanced solid tumors; its precise mechanism of action has not been publicly disclosed as of April 2025[5][7][4].
02
Targets
B7-H3PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on TJ271 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TJ271 + pembrolizumab.